There’s a quiet revolution happening in the world of metabolic health. If you’ve been following the rise of GLP-1 drugs like Ozempic and Mounjaro, you know they’ve shifted the conversation around obesity from “willpower and diet” to “biology and chemistry.” Now, Viking Therapeutics is stepping up with something that could change the game yet again.
They just announced positive Phase 2 results for their oral weight-loss drug candidate, VK2735. And the data isn’t just promising — it’s eyebrow-raising.
The Highlights (a.k.a. Why This Matters)
- Weight loss up to 12.2% in just 13 weeks (that’s without plateauing — meaning more weight loss might come with longer dosing).
- Placebo-adjusted reductions of nearly 11% — which puts it in the ballpark of today’s top-performing injectables.
- 80% of participants hit 10%+ weight loss, compared to just 5% on placebo.
- Safe and well-tolerated with most side effects being mild/moderate GI issues, similar to other GLP-1/GIP drugs.
And here’s the kicker: this wasn’t an injection. It was a once-daily oral pill.
Why an Oral Pill Could Be the “Next Wave”
Right now, drugs like Ozempic (semaglutide) and Mounjaro (tirzepatide) are leading the pack — but they’re injectables. Millions of people use them weekly, but let’s be honest: if given the choice between a needle and a pill, most would pick the pill.
Viking’s VK2735 is being developed in both oral and injectable forms. That flexibility matters. Oral drugs could expand access, improve compliance, and potentially reduce costs over time.
A Peek Inside the Data
Here’s how it broke down over 13 weeks:
- Placebo: –1.3% body weight
- VK2735 (120 mg): –12.2% body weight
- VK2735 (90 mg): –11.1% body weight
- Even the mid-range doses hit 7–9% reductions.
And importantly — the weight loss curve didn’t flatten. Patients were still losing weight at Week 13, suggesting the potential for even bigger outcomes in longer studies.
Safety Profile: What About Side Effects?
As with most GLP-1/GIP drugs, the main complaints were GI-related: nausea, vomiting, diarrhea, constipation.
- Nausea: 58% of VK2735 users (vs 48% placebo)
- Vomiting: 26% (vs 10% placebo)
- Almost all were mild to moderate and tended to improve after the first few weeks.
Discontinuation rates were higher in treatment groups (28% vs 18% placebo), but still considered manageable — especially when compared to other drugs in this class.
The Experimental Twist: Weight Maintenance
Here’s something really interesting. Viking tested a dose transition strategy: ramping patients up to 90 mg, then down-titrating to 30 mg daily.
The result? Patients maintained their weight loss even after reducing the dose.
That could hint at a new paradigm for long-term weight management:
- Start strong.
- Then scale back to a lower, more tolerable maintenance dose.
Think of it as a “sprint + sustain” model for weight loss therapy.
Why This Could Be Huge
We’re looking at a world where:
- Obesity treatments move beyond injections.
- Weight maintenance becomes more sustainable.
- Dual-agonist therapies (GLP-1 + GIP) continue to outperform single-agonist strategies.
This isn’t just a biotech milestone — it’s potentially the beginning of a broader health revolution.
Final Thoughts
If Viking can replicate these results in longer Phase 3 trials, VK2735 could become a direct competitor to Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Mounjaro/Zepbound).
For patients, it could mean:
- More options.
- Easier access.
- And maybe, just maybe, a pill that does what injections do today.
As Viking CEO Brian Lian put it:
“The progressive nature of the weight loss curves suggests the potential for further improvement with longer dosing periods… transitioning patients from higher doses to low oral doses represents a promising approach to weight maintenance therapy.”
Translation: This is just the beginning.
Key Takeaway:
Obesity treatment is entering a new chapter. Pills, not needles. Maintenance, not yo-yoing. And science is moving faster than ever
